Iatrogenic Cushing's syndrome by an interaction between cobicistat and fluticasone: a case report

Iatrogenic Cushing's syndrome by an interaction between cobicistat and fluticasone: a case report

SUMMARY We report a case of iatrogenic Cushing's syndrome associated with an interaction between cobicistat and fluticasone in a seropositive woman treated with elvitegravir/cobicistat/emtricitabina/TAF (Genvoya®). This case highlights the importance to review interactions between antirretroviral therapy and other drugs, especially when antirretroviral scheme includes protease inhibitors enhanced with ritonavir or cobicistat. These enhancers interfere the cytochrome P-450 metabolic pathway. A large number of drugs are metabolized by cytochrome P-450 and may be altered by cobicistat or ritonavir.

Saved in:
Bibliographic Details
Main Authors: Matilla García,E, Apezteguía Fernández,CA, Rodríguez Vargas,B, Moreno Díaz,R, Bautista Sanz,MP, Hoyo Gil,L
Format: Digital revista
Language:English
Published: Organización de Farmacéuticos Ibero-Latinoamericanos 2021
Online Access:http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1699-714X2021000200204
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1699-714X2021000200204
record_format ojs
spelling oai:scielo:S1699-714X20210002002042022-05-23Iatrogenic Cushing's syndrome by an interaction between cobicistat and fluticasone: a case reportMatilla García,EApezteguía Fernández,CARodríguez Vargas,BMoreno Díaz,RBautista Sanz,MPHoyo Gil,L HIV cobicistat fluticasone Cushing's syndrome SUMMARY We report a case of iatrogenic Cushing's syndrome associated with an interaction between cobicistat and fluticasone in a seropositive woman treated with elvitegravir/cobicistat/emtricitabina/TAF (Genvoya®). This case highlights the importance to review interactions between antirretroviral therapy and other drugs, especially when antirretroviral scheme includes protease inhibitors enhanced with ritonavir or cobicistat. These enhancers interfere the cytochrome P-450 metabolic pathway. A large number of drugs are metabolized by cytochrome P-450 and may be altered by cobicistat or ritonavir.Organización de Farmacéuticos Ibero-LatinoamericanosRevista de la OFIL v.31 n.2 20212021-06-01journal articletext/htmlhttp://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1699-714X2021000200204en
institution SCIELO
collection OJS
country España
countrycode ES
component Revista
access En linea
databasecode rev-scielo-es
tag revista
region Europa del Sur
libraryname SciELO
language English
format Digital
author Matilla García,E
Apezteguía Fernández,CA
Rodríguez Vargas,B
Moreno Díaz,R
Bautista Sanz,MP
Hoyo Gil,L
spellingShingle Matilla García,E
Apezteguía Fernández,CA
Rodríguez Vargas,B
Moreno Díaz,R
Bautista Sanz,MP
Hoyo Gil,L
Iatrogenic Cushing's syndrome by an interaction between cobicistat and fluticasone: a case report
author_facet Matilla García,E
Apezteguía Fernández,CA
Rodríguez Vargas,B
Moreno Díaz,R
Bautista Sanz,MP
Hoyo Gil,L
author_sort Matilla García,E
title Iatrogenic Cushing's syndrome by an interaction between cobicistat and fluticasone: a case report
title_short Iatrogenic Cushing's syndrome by an interaction between cobicistat and fluticasone: a case report
title_full Iatrogenic Cushing's syndrome by an interaction between cobicistat and fluticasone: a case report
title_fullStr Iatrogenic Cushing's syndrome by an interaction between cobicistat and fluticasone: a case report
title_full_unstemmed Iatrogenic Cushing's syndrome by an interaction between cobicistat and fluticasone: a case report
title_sort iatrogenic cushing's syndrome by an interaction between cobicistat and fluticasone: a case report
description SUMMARY We report a case of iatrogenic Cushing's syndrome associated with an interaction between cobicistat and fluticasone in a seropositive woman treated with elvitegravir/cobicistat/emtricitabina/TAF (Genvoya®). This case highlights the importance to review interactions between antirretroviral therapy and other drugs, especially when antirretroviral scheme includes protease inhibitors enhanced with ritonavir or cobicistat. These enhancers interfere the cytochrome P-450 metabolic pathway. A large number of drugs are metabolized by cytochrome P-450 and may be altered by cobicistat or ritonavir.
publisher Organización de Farmacéuticos Ibero-Latinoamericanos
publishDate 2021
url http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1699-714X2021000200204
work_keys_str_mv AT matillagarciae iatrogeniccushingssyndromebyaninteractionbetweencobicistatandfluticasoneacasereport
AT apezteguiafernandezca iatrogeniccushingssyndromebyaninteractionbetweencobicistatandfluticasoneacasereport
AT rodriguezvargasb iatrogeniccushingssyndromebyaninteractionbetweencobicistatandfluticasoneacasereport
AT morenodiazr iatrogeniccushingssyndromebyaninteractionbetweencobicistatandfluticasoneacasereport
AT bautistasanzmp iatrogeniccushingssyndromebyaninteractionbetweencobicistatandfluticasoneacasereport
AT hoyogill iatrogeniccushingssyndromebyaninteractionbetweencobicistatandfluticasoneacasereport
_version_ 1755941069925646336

Similar Items